The main goal of this study is to test the experimental drug mirdametinib in hopes of finding a treatment that may be effective against low-grade glioma brain tumors in children, adolescents and young adults.
Age:
At least 2 years old and younger than 25 years old.
To study the side effects and best dose of MK-3475 (pembrolizumab) and to see how well it works in treating younger patients with high-grade gliomas (brain tumors), diffuse intrinsic pontine gliomas (brain stem tumors), or hypermutated brain tumors that have come back, progressed or have not responded to previous treatment
The main goal of this study is to test the experimental drug mirdametinib in hopes of finding a treatment that may be effective against low-grade glioma brain tumors in children, adolescents and young adults.
Age:
At least 2 years old and younger than 25 years old.
This study uses a risk-directed approach to find out which types of treatment will work best and have the fewest side effects for infants and children with medulloblastoma.
